Sorrento Therapeutics Inc

NASDAQ:SRNE   11:53:03 AM EDT
8.44
+0.21 (+2.55%)
Products

Sorrento Therapeutics Says Phase 2 Trial Of RTX For OA Pain To Proceed Following FDA Clearance

Published: 07/06/2021 19:15 GMT
Sorrento Therapeutics Inc (SRNE) - FDA Clears Sorrento Phase 2 Trial of Non-opioid Product Candidate Resiniferatoxin (rtx) for Treatment of the Knee Pain in Osteoarthritis (oa) Patients.
Sorrento Therapeutics Inc - Phase 2 Trial of Rtx for Oa Pain to Proceed Following FDA Clearance.
Sorrento Therapeutics Inc - Rtx Clinical Development Program Continues, With Phase 2 and 3 Clinical Trials Planned in Larger Patient Populations.
Sorrento Therapeutics Inc - First Phase 2 Trial Will Focus on Identifying Recommended Phase 3 Dose.